Authors
Latest:
Adding Nivolumab to Induction Chemotherapy Safe in Younger AML PatientsThis video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia.
Latest:
Skin Lesions in Patient With Metastatic Breast CancerA 57-year-old woman with metastatic HER2/neu-positive breast cancer started treatment with a combination of docetaxel, pertuzumab, and trastuzumab. On the fourth cycle the patient complained of mild irritation and a skin rash on her left upper extremity. What is your diagnosis?
Latest:
Is Molecular Remission the Goal When Treating Myeloma?In this interview we discuss the goals of therapy in multiple myeloma, treatment combinations and transplantation, and how markers such as minimal residual disease are used.
Latest:
DLBCL Trials May Exclude Patients Who Need Novel Therapies MostIn this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.
Latest:
Precision Imaging in Breast CancerThis video highlights four posters from SABCS on the use of mammography, magnetic resonance imaging, and radiomics as biomarkers for treatment response.
Latest:
Clinical Pearls for Community Oncologists Treating MyelofibrosisThe panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.
Latest:
Preventing, Treating Relapse After ASCT in Hematologic Malignancy PatientsThis video highlights research into the use of post-transplant therapies to prevent or treat disease recurrence following allogeneic stem cell transplantation.
Latest:
Identifying Children With Leukemia Predisposition SyndromesThis video reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.
Latest:
Immunotherapies Could Play Role in CALR-Positive Myeloproliferative NeoplasmsThis video highlights a study that establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.
Latest:
Could Single-Cell RNA Sequencing Help Personalize Multiple Myeloma Treatment?This video highlights research that found that single-cell RNA sequencing can better characterize patients and potentially improve multiple myeloma treatment in a more personalized manner.
Latest:
Expert Insight and Future Perspectives for Follicular LymphomaPanelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
Latest:
Novel Treatment Approaches in Higher-Risk Myelodysplastic SyndromesThis video reviews novel treatment approaches in the management of higher-risk myelodysplastic syndromes.
Latest:
Predicting Response to Immunotherapy With a Mathematical ModelIn this interview, we discuss a mathematical model that was created to predict patient response to immunotherapy for cancer treatment.
Latest:
Predicting Response to Immunotherapy With a Mathematical ModelIn this interview, we discuss a mathematical model that was created to predict patient response to immunotherapy for cancer treatment.
Latest:
POINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic CancerASCO clinical practice guidelines recommend resection followed by treatment with gemcitabine and capecitabine as the standard of care; however, neoadjuvant therapy is also considered an appropriate alternative.
Latest:
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic CancerNeoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.
Latest:
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic CancerNeoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.
Latest:
Woman With Rare Cause of Rectal BleedingA 56-year-old Caucasian woman presented to her primary care physician with a 3-month history of intermittent bright red rectal blood with defecation. At her initial visit, a digital rectal examination, anoscopy, and a pelvic examination with DNA testing for high-risk HPV were performed; all results were negative. She was referred for a colonoscopy, which revealed an abnormal area with a 3 × 4–cm mass in the rectum at a distance of 10 cm from the anal verge.
Latest:
Woman With Rare Cause of Rectal BleedingA 56-year-old Caucasian woman presented to her primary care physician with a 3-month history of intermittent bright red rectal blood with defecation. At her initial visit, a digital rectal examination, anoscopy, and a pelvic examination with DNA testing for high-risk HPV were performed; all results were negative. She was referred for a colonoscopy, which revealed an abnormal area with a 3 × 4–cm mass in the rectum at a distance of 10 cm from the anal verge.
Latest:
Fear of Cancer Recurrence: A Practical Guide for CliniciansWith increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Latest:
Fear of Cancer Recurrence: A Practical Guide for CliniciansWith increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Latest:
Fear of Cancer Recurrence: A Practical Guide for CliniciansWith increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Latest:
Fear of Cancer Recurrence: A Practical Guide for CliniciansWith increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Latest:
Fear of Cancer Recurrence: A Practical Guide for CliniciansWith increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Latest:
Fear of Cancer Recurrence: A Practical Guide for CliniciansWith increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Latest:
Newly Diagnosed Glioblastoma: A Review on Clinical ManagementThis review focuses on clinical developments and management of newly diagnosed glioblastoma, and includes a discussion about the incorporation of molecular features into the classification of this disease.
Latest:
Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future DirectionsIn Part 2 of this review article, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation, as well as provide clinicians with a comprehensive overview by covering the key investigations that have brought us to our current state of knowledge, and studies that may guide future interventions.
Latest:
Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future DirectionsIn Part 2 of this review article, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation, as well as provide clinicians with a comprehensive overview by covering the key investigations that have brought us to our current state of knowledge, and studies that may guide future interventions.
Latest:
Improving Childhood Cancer Survivor Care Through Web-Based PlatformsHere, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Latest:
Improving Childhood Cancer Survivor Care Through Web-Based PlatformsHere, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
